Supernus Pharmaceuticals, Inc.SUPN
What Supernus Pharmaceuticals, Inc. does.
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.
The Company was incorporated in Delaware, commenced operations in 2005, became publicly traded in 2012, and is listed on the NASDAQ Stock Exchange under the ticker symbol SUPN. Our principal executive offices are located in Rockville, Maryland. Our extensive expertise in product development has been built over the past 30 years: initially as a stand-alone development organization; then, as a United States (U.S.) subsidiary of Shire Plc (Shire, a subsidiary of Takeda Pharmaceutical Company Ltd.); then upon our acquisition of substantially all of the assets of Shire Laboratories, Inc. in 2005, as Supernus Pharmaceuticals, Inc.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Net income | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M |
| Free cash flow | $134.9M | — | $116.4M | $110.5M | $171.2M | $46.0M |
More on SUPN.
- Supernus Pharmaceuticals, Inc. summary
- Supernus Pharmaceuticals, Inc. financial statements
- Supernus Pharmaceuticals, Inc. key metrics
- Supernus Pharmaceuticals, Inc. health scores and style box
- Supernus Pharmaceuticals, Inc. earnings
- Supernus Pharmaceuticals, Inc. dividends
- Supernus Pharmaceuticals, Inc. valuation
- Supernus Pharmaceuticals, Inc. ownership and insiders
- Supernus Pharmaceuticals, Inc. peers
Figures from Supernus Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.